Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150946 | 0.87 | TLR8 (0.44) | ACP1KDM4ETP53 | |
| SCHEMBL5149119 | 0.87 | GSK3B (0.39) | KDM4ETP53 | |
| SCHEMBL5149173 | 0.86 | HTR7 (0.37) | TP53 | |
| SCHEMBL5152634 | 0.86 | P2RX3 (0.37) | KDM4EMEN1KMT2ATP53F7 | |
| SCHEMBL5150823 | 0.85 | KDM4E (0.39) | ATRKDM4ETP53F7F3 | |
| SCHEMBL5149144 | 0.85 | LDHA (0.39) | ATRKDM4ETP53 | |
| SCHEMBL5147928 | 0.85 | MEN1 (0.42) | KDM4EMEN1KMT2ATP53 | |
| SCHEMBL6134030 | 0.84 | CALCA (0.43) | CALCAKAT2BTLR9ACP1 | |
| SCHEMBL5149090 | 0.83 | HIF1A (0.45) | TLR9ACP1 | |
| SCHEMBL5152713 | 0.83 | ACHE (0.43) | KAT2BTLR9ACP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| CN-1938296-A | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists | ASTELLAS PHARMA INC (JP) | 2007-03-28 | — | — | CN | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | CALCA 2493/4885ATR 2780/4885KAT2B 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.